Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding telitacicept to standard care nearly doubled complete kidney response rates in lupus nephritis patients compared to standard care alone. In a study of 112 patients, over two-thirds achieved full renal response at 24 weeks with the combination — and the benefit only grew over time. Patients on telitacicept also needed less steroid medication.
A new retrospective study out of China suggests that adding telitacicept to standard-of-care therapy could be a meaningful advance for patients with proliferative lupus nephritis (LN). Researchers analyzed 112 patients with biopsy-proven Class III/IV LN and found that those receiving weekly subcutaneous telitacicept alongside standard therapy achieved dramatically higher rates of complete renal response compared to those on standard care alone.
The benefits were evident early and kept building. By week 52, 84.1% of patients in the telitacicept group achieved complete renal response, compared to 63% in the control group. Patients on telitacicept also required lower glucocorticoid (steroid) doses and showed significantly improved disease activity scores — a meaningful win for reducing long-term steroid-related side effects.
Why it matters: Lupus nephritis is one of the most serious complications of systemic lupus erythematosus, and current standard therapies don't always achieve adequate kidney protection. These findings position telitacicept as a promising add-on strategy that could improve long-term kidney outcomes while reducing steroid burden — though larger, prospective trials are needed to confirm these results.
